Drugs / MuSK-CAART
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05451212 | Nov 2022 → Jul 2025 | muscle-specific tyrosine kinase-associated myasthenia gravis | Cabaletta Bio | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2022-03-01 | Cabaletta Bio | Regulatory U.S. Food and Drug Administration Grants Cabaletta Bio Fast Track Designation for MuSK-CAART cabalettabio.com ↗ |
| 2020-05-18 | Cabaletta Bio | Results Cabaletta Bio Announces Presentation of Data Supporting MuSK-CAART Development for the Treatment of the MuSK form of Myasthenia Gravis at the AAN 2020 Science Highlights Virtual Platform cabalettabio.com ↗
In vivo preclinical data show that Chimeric AutoAntibody Receptor (CAAR) T cells were able to specifically recognize and eliminate anti-MuSK antibody-expressing B cells while sparing control B cells |
| 2019-10-07 | Cabaletta Bio | Results Cabaletta Bio Announces Presentation of Preclinical Data Showing Specific CAAR T Activity against Anti-MuSK Expressing B Cells cabalettabio.com ↗
today announced a preclinical in vitro study demonstrating specific killing of anti-muscle-specific tyrosine kinase (MuSK) antibody-expressing target cells by Chimeric AutoAntibody Receptor T (CAAR T) cells. |
All press releases naming this drug 4 releases
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MuSK-CAART | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05451212 ↗ |
| Modality | Cell therapy | “an investigational cell therapy, MuSK-CAART” NCT05451212 ↗ |
| Route | Intravenous | “Intravenous infusion of MuSK-CAART at different doses” NCT05451212 ↗ |